Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Citations of this article
Mendeley users who have this article in their library.
Get full text


Oncofetal protein SALL4 is critical for cancer cell survival. Targeting SALL4, however, is only applicable in a fraction of cancer patients who are positive for this gene. To overcome this limitation, we propose to induce a cancer vulnerability by engineering a partial dependency upon SALL4. Following exogenous expression of SALL4, SALL4-negative cancer cells became partially dependent on SALL4. Treatment of SALL4-negative cells with the FDAapproved hypomethylating agent 5-aza-20-deoxycytidine (DAC) resulted in transient upregulation of SALL4. DAC pretreatment sensitized SALL4-negative cancer cells to entinostat, which negatively affected SALL4 expression through a microRNA, miRNA- 205, both in culture and in vivo. Moreover, SALL4 was essential for the efficiency of sequential treatment of DAC and entinostat. Overall, this proof-of-concept study provides a framework whereby the targeting pathways such as SALL4-centered therapy can be expanded, sensitizing cancer cells to treatment by transient target induction and engineering a dependency. Significance: These findings provide a therapeutic approach for patients harboring no suitable target by induction of a SALL4- mediated vulnerability. _2021 American Association for Cancer Research.




Yang, J., Gao, C., Liu, M., Liu, Y. C., Kwon, J., Qi, J., … Chai, L. (2021). Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. Cancer Research, 81(23), 6018–6028.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free